Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
IN8bio ( (INAB) ) has issued an announcement.
On June 2, 2025, IN8bio announced positive Phase 1 trial results for INB-200 in newly diagnosed glioblastoma multiforme, presented at the 2025 American Society of Clinical Oncology Annual Meeting. The trial showed that repeated doses of INB-200 extended median progression-free survival to 16.1 months, significantly surpassing the standard-of-care protocol’s 6.9 months. The treatment was well-tolerated, with no serious toxicities observed, and demonstrated potential to improve patient outcomes, including the ability for some patients to return to work. These findings suggest that INB-200 could represent a novel therapeutic direction for solid tumor cancers like glioblastoma, enhancing survival without adding toxicity.
The most recent analyst rating on (INAB) stock is a Buy with a $7.50 price target. To see the full list of analyst forecasts on IN8bio stock, see the INAB Stock Forecast page.
Spark’s Take on INAB Stock
According to Spark, TipRanks’ AI Analyst, INAB is a Underperform.
IN8bio’s stock score reflects significant financial challenges, typical of early-stage biotechnology companies. The financial performance is hindered by substantial operational losses and reliance on external funding, while technical analysis shows bearish market trends. Valuation remains speculative with a negative P/E ratio, emphasizing the high-risk nature of investing in developmental biotech firms.
To see Spark’s full report on INAB stock, click here.
More about IN8bio
IN8bio is a clinical-stage biopharmaceutical company focused on developing gamma-delta T cell-based immunotherapies for cancer and autoimmune diseases. Their lead program, INB-100, targets acute myeloid leukemia, while the INB-200 and INB-400 programs focus on glioblastoma, utilizing autologous DeltEx DRI gamma-delta T cells in combination with standard care.
Average Trading Volume: 2,618,666
Technical Sentiment Signal: Sell
Current Market Cap: $13.45M
See more insights into INAB stock on TipRanks’ Stock Analysis page.